Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor
Asia
Europe, Middle East, Africa
North America
Mérieux Alliance Becomes Institut Mérieux
07 December, 2009
Alain Mérieux confirms the Institute’s commitment to meeting new medical and public health challenges
Long-Term Strategic Partnership Between bioMérieux and the CEA to Develop Innovative Technologies for Infectious Disease Management
03 December, 2009
bioMérieux and the CEA (French Atomic Energy Commission) announce today a long-term strategic partnership, intensifying their research collaboration to develop novel technologies for improved infectious disease management.
bioMérieux's TEMPO® Gains Approval for Testing E. Coli in Food Samples
01 December, 2009
pr_tempo_small_thumb19.jpg bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that TEMPO® EC, an automated quality indicator test for the fast enumeration of Escherichia coli in food products, has been granted Official Methods of Analysis (OMA) approval by AOAC INTERNATIONAL. This added level of certification assures TEMPO EC users that the test meets stringent AOAC standards for excellence in indicator testing.
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
17 November, 2009
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.
bioMérieux's VIDAS System Simplifies the Detection of Salmonella and E. coli O157 Including H7 Strains for the Meat Industry
10 November, 2009
50_078minividasblue_thumb19.jpg bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VIDAS® Salmonella Xpress (SLMX) and VIDAS® UP E. coli O157 (Including H7) kits have been validated by AFNOR Certification according to the ISO 16140 standard. These validations cover the testing of raw beef and veal.
bioMérieux Unveils its Groundbreaking Culture Media Range for Sterility Control of Aseptic Pharmaceutical Plants
07 November, 2009
New range will simplify testing for the pharmaceutical industry.
Alain Pluquet's Appointment
03 November, 2009
A world leader in the field of in vitro diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO).
bioMérieux Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Screening Tool to its Arsenal
28 October, 2009
New chromogenic media provides cost-effective MRSA identification for hospitals and labs
bioMérieux - Business Review for the Nine Months Ended September 30, 2009
20 October, 2009
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2009.